Results 61 to 70 of about 20,052 (248)

Potentiation of the restorative effect of semaglutide on metabolic and hormonal parameters in rats with diet-induced type 2 diabetes mellitus with intranasally administered insulin

Сибирский научный медицинский журнал
Semaglutide, a glucagon-like peptide-1 receptor agonist, is widely used for the treatment of type 2 diabetes mellitus (DM2), but it is not effective in some patients, which requires the development of approaches to enhance its therapeutic effect.
K. V. Derkach, N. E. Basova, A. O. Shpakov   +2 more
doaj   +1 more source

Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review

Frontiers in Endocrinology, 2023
PurposeThis study aimed to perform a network meta-analysis to objectively evaluate the efficacy and safety of 10 Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in combination with metformin that is approved for use worldwide in patients with type 2
Zeyu Xie, Jia Hu, Hangye Gu, Mengting Li, Jisheng Chen   +4 more
doaj   +1 more source

Characteristics and outcomes of diabetic patients with an implantable cardioverter defibrillator in a real world setting: results from the Israeli ICD registry [PDF]

, 2016
AIMS: There are limited data regarding the effect of diabetes mellitus (DM) on the risks of both appropriate and inappropriate implantable cardioverter defibrillator (ICD) therapy.
Alexander Tenenbaum, Alon Barsheshet, Boris Strasberg, Enrique Z. Fisman, Gregory Golovchiner, Hillel Steiner, Ilan Goldenberg, Mahmoud Suleiman, Michael Geist, Michael Glikson, Moshe Swissa, null null   +11 more
core   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Glucagon-like peptide-1 and its class B G protein-coupled receptors: A long march to therapeutic successes [PDF]

, 2016
Theglucagon-likepeptide (GLP)-1receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secretedfromthreemajor tissues inhumans,enteroendocrine L cells in the distal intestine, a cells in the ...
Adelhorst, Alastair J. H. Brown, Andersen, Avatapalle, Belin, Brown, Caihong Zhou, Chris de Graaf, Dan Donnelly, Davis, Dehua Yang, Denise Wootten, Denker, Dods, Drucker, Elahi, Ferguson, Gallwitz, Goodman, Green, Grynkiewicz, Gustavson, Göke, Hendrick, Heppner, Hjorth, Holst, Holst, Huang, Jendle, Jesper Lau, Jiayu Liao, Jiejie Deng, Jung-Mo Ahn, La Barre, Laurence J. Miller, Li, Locatelli-Hoops, Lund, Madeleine M. Fletcher, Ming-Wei Wang, Mojsov, Mojsov, Nauck, Nauck, Orskov, Orskov, Patrick M. Sexton, Pocai, Prentki, Rhodes, RICHARD DEQUAN YE, Sancho, Shiue, Steensgaard, Tang-Christensen, Tibaduiza, Tomkin, Unson, Wettergren, Widmann, Wild, Willard, Zunz   +63 more
core   +3 more sources

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Impact of semaglutide on osteoarthritis risk in patients with obesity: A retrospective cohort study

Obesity Science & Practice
Background Osteoarthritis (OA) is a prevalent degenerative joint disorder. While the effect of obesity on OA is well documented, less is known about the effect of semaglutide on OA.
Onur Baser, Lauren Isenman, Sefika Baser, Gabriela Samayoa   +3 more
doaj   +1 more source

Efficacy, safety, and patient satisfaction with oral semaglutide: first single-centre clinical experience

Journal of International Medical Research, 2023
Objective To explore the effects of oral semaglutide on glycaemic parameters, body weight, and satisfaction in the first recipient patients with type 2 diabetes mellitus in Slovenia, in a real-world clinical practice setting.
Miodrag Janić, Marija Jovanović, Andrej Janež, Mojca Lunder   +3 more
doaj   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer, Eliza J. McEwin, Zhicheng Wang, Joel Lexchin, Barbara Mintzes   +4 more
wiley   +1 more source

Oral Semaglutide [PDF]

Clinical Diabetes, 2020
Sally, Hughes, Joshua J, Neumiller
openaire   +2 more sources